Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

262.03 5.90 −2.20%
Market cap
$40.5B
P/E
48.4×
Fwd P/E
34.7×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a

Illumina, Inc. (ILMN) Total debt

Alert me on Total debt

Illumina, Inc.'s total debt at the end of fiscal 2025 was $1.5B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.5B. Over the past ten years it has ranged from $1.1B (fiscal 2016) to $2.0B (fiscal 2018); the current reading is higher than 82% of that period. Illumina, Inc. ranks 15th of 50 Diagnostics & Research companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $1.5B 0.00%
FY2024 $1.5B 0.07%
FY2023 $1.5B 0.13%
FY2022 $1.5B (12.27%)
FY2021 $1.7B 43.16%
FY2020 $1.2B (0.17%)
FY2019 $1.2B (40.61%)
FY2018 $2.0B 67.53%
FY2017 $1.2B 12.67%
FY2016 $1.1B (2.99%)

Quarterly newest first

Period Total debt Change
Jun 2026 $1.5B 0.07%
Mar 2026 $1.5B 0.00%
Dec 2025 $1.5B 49.90%
Sep 2025 $994.0M (33.38%)
42 more quarters

Against its own ten years

Low $1.1B High $2.0B
Ten-year median $1.5B
Current reading's percentile 82

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on ILMN